Lowest Price Guaranteed
Pages
298
Last Updated
January 2026
View Count
10821
The global virtual biopsy market, valued at USD 0.78 billion in 2025, is projected to reach USD 0.85 billion in 2026 and USD 3.02 billion by 2035, representing a CAGR of 15% during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
The new research study consists of industry trends, detailed market analysis, competitive landscape, product competitiveness analysis, partnership and collaborations, funding and investments, patent analysis, publication analysis and market impact analysis. Further, the report also includes market forecast and opportunity analysis.
The virtual biopsy market growth over the next decade is expected to be driven by advancements in imaging and data storage capacities. These advancements enable researchers and healthcare professionals to capture and maintain high-resolution images for efficient result analysis. Further, the utilization of advanced imaging techniques, such as magnetic resonance imaging (MRI), ultrasound and optical coherence tomography (OCT), for the extraction of 3D and high contrast images has attributed to drive the market growth.
 |
 |
 |
For many years, healthcare professionals have utilized conventional biopsy procedures for analyzing the patient’s condition through surgical sample acquisition. However, these traditional methods may lead to several complications, including patient discomfort, infections and hemorrhage after incision. Additionally, conventional biopsies are often costly, encompassing expenses related to sample collection, operating room maintenance and surgical interventions.
According to the Indian Council of Medical Research (ICMR), the incidence of cancer cases is projected to rise from 1.4 million in 2022 to 1.5 million by 2025. Consequently, there is a growing demand among physicians for safer and more efficient alternatives to conventional biopsy techniques that can accommodate a large population.
 |
 |
 |
Considering these health concerns, the virtual biopsy technique has gained traction as a critical tool for non-invasive disease detection and prognosis. This innovative approach offers a promising solution by minimizing risks and enhancing the overall screening process for patients.
Virtual biopsy provides comprehensive insights about patients’ condition by utilizing advanced artificial intelligence (AI) integrated software for detailed analysis of extracted sample images. This innovative approach is crucial for assessing drug responses during treatment without the risks associated with surgical procedures, making it a convenient tool for treatment planning. Further, virtual biopsy is employed to analyze lesion heterogeneity through automated software, allowing for precise discrimination of lesion types. Given these latest advancements in virtual biopsy techniques, the growing need for effective patient care management, early detection and routine diagnostics can be efficiently addressed in the future.
 |
 |
 |
However, despite their benefits, the employment of virtual biopsy techniques faces several challenges. One of the most significant issues is the need to comply with complex and intricate regulatory guidelines established by authorities, such as US food and drug administration FDA, European Union (EU) and many more for market approvals of virtual biopsy devices. Moreover, presence of limited clinical trials on virtual biopsy efficacy may foster skepticism amongst stakeholders, including doctors, patients and insurance firms, regarding the validation of the results.
Additionally, inconsistencies in adequately training physicians on software operation can hinder the integration of virtual biopsy technique into existing workflows. Shreeya Agrawal, Associate, Roots Analysis states “with the rising need for safer diagnostic solutions and continuous improvements in imaging technologies and AI integrated software for result interpretation, the virtual biopsy market is anticipated to experience significant growth during the forecast period.”
The research report presents an in-depth analysis of various virtual biopsy device developers, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Current Market Size | $0.85 billion | |
| Market Size 2035 | $3.02 billion | |
| CAGR (Till 2035) | 15% | |
| Type of Target Therapeutic Area |
|
|
| Type of Cancer Targeted |
|
|
| Type of Imaging Technology |
|
|
| End Users |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
One of the key objectives of this market report was to estimate the current market size, future opportunity and the growth potential for virtual biopsy device developers, over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution till 2035.
The market report also features the likely distribution of the current and forecasted opportunity for virtual biopsy device developers in the market across various segments, such as target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, ophthalmological disorders, endocrine disorders, gastrointestinal disorders and others), type of cancer targeted (solid malignancies, breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer and others), end users (hospitals and clinics, research institutes and diagnostic centers and others), geographical regions (North America (US and Canada), Europe (Germany, France, Italy, UK, Spain, Switzerland and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia and Rest of Asia-Pacific), Middle East and North Africa (Saudi Arabia, Israel, Egypt, and Rest of Middle East and North Africa), and Latin America (Brazil, Mexico, Argentina and Rest of Latin America)) and leading players.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three virtual biopsy market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s evolution. The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
This segment highlights the distribution of the global market across different target therapeutic areas, namely oncological disorders, neurological disorders, cardiovascular disorders, ophthalmological disorders, endocrine disorders, gastrointestinal disorders and others.
Currently, the oncological disorders market segment holds the largest virtual biopsy market share (>25%). This dominance is primarily attributed to the physicians preference for diagnostic devices that facilitate non-invasive sample extraction for cancer diagnostics . Virtual biopsy devices fulfill this need by utilizing advanced imaging technologies such as magnetic resonance imaging, computed tomography and X-ray for image capturing and data analysis.
The virtual biopsy market is segmented into different types of target cancers, namely solid malignancies, breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer and others. Currently, solid malignancies segment holds the majority share (~35%) in the overall market. This can be attributed to the fact that amongst varied types of cancers diagnosed, solid tumors account for approximately 90% of all adult cancers.
This high prevalence not only increases the demand for diagnostic solutions but also highlights the essential need for advanced technologies, such as virtual biopsies, that can effectively target these common cancers. Following solid malignancies, breast cancer represents the second most significant type of cancer targeted.
The virtual biopsy market is segmented into different types of imaging technology, namely magnetic resonance imaging, computed tomography, X-ray, ultrasound and others. Currently, the magnetic resonance imaging segment holds the majority share (>30%) in the overall market. This can be attributed to the fact that magnetic resonance imaging (MRI) utilizes safer magnetic and radio waves for image acquisition. Additionally, MRI provides a comprehensive 360-degree view of the sample, facilitating easier and effective analysis of the patient’s condition.
The global market is segmented into different end users, namely hospitals and clinics, research institutions and diagnostic centers, and others. Currently, hospital and clinics segment holds the majority share (~70%) in the overall market. This percentage distribution is unlikely to change during the forecast period, till 2035, owing to the fact that virtual biopsy devices offer screening, diagnosis and prognosis of ailments in the healthcare sector for efficient patient care management, thereby generating a high demand for these devices in the hospitals and clinics.
This segment highlights the distribution of virtual biopsy market size across various geographies, namely North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Based on our market analysis, currently, North America is likely to occupy the highest share (~40%) in the overall market. This can be attributed to the allocation of substantial amounts of budget, in this region for extensive research and development in the healthcare domain and enhance existing technologies.
Further, it is worth noting that the market for virtual biopsy in Latin America is poised to grow at a highest CAGR of 11.55%, during the forecast period.
The "Virtual Biopsy Market: Industry Trends and Global Forecasts, till 2035" report features an extensive study of the current market landscape, market size and future opportunities for virtual biopsy device developers, during the given forecast period. The market report highlights the efforts of several stakeholders in this domain. Key takeaways of the market data analysis are briefly discussed below.
According to National Cancer Registry Programme Report, the oncological disorder cases are expected to rise by 12.8% by current year, highlighting the urgent need for rapid diagnostic result generating tools and address the increasing patient load. Virtual biopsy serves as an advance solution, providing results with a turnaround time of just 15 minutes, compared to conventional biopsy, which may take ~4 days for complete analysis. Hence, virtual biopsy technique can aid in providing faster and accurate results catering larger population size in comparatively lesser time frame.
Presently, around 25 virtual biopsy device developers are involved in this domain and the current market landscape features the presence of very large, large, mid-sized, small and very small companies. Further, it is worth mentioning that majority (about 60%) of the virtual biopsy device developers are headquartered in Europe. This can be attributed to the fact that developed regions, such as Europe has extensively developed a supportive ecosystem ideal for upcoming companies of virtual biopsy to set up businesses. Additionally, the rising prevalence of oncological disorders has spurred demand for virtual biopsy devices, prompting the establishment of numerous companies in this region.
In 2025, the International Agency for Research on Cancer (IARC) reported that around 4 million new cancer cases will be diagnosed across Europe. This alarming statistic underscores the urgent need for effective medical interventions, along with the rapid screening of oncological ailments to effectively make treatment plans before cancer propagates. Hence, developers related to virtual biopsy designed innovative and advanced devices for rapid early detection and diagnostic approach. Notable examples of leading players based in Europe include (established post-2019, in alphabetical order) HepaVue, KENKO Imalytics and PONS.
Researchers at esteemed universities such as Stanford Medicine and Imperial College London have also recently shown positive outcomes with virtual biopsy.
In recent years, several partnerships and collaborations have been established by stakeholders in virtual biopsy domain, enabling companies to expand their respective product portfolios and enhance their capabilities and visibility in this domain. It is worth highlighting that majority of the partnerships signed in this industry are technology integration agreements. For instance, in 2024, GE Healthcare and Amazon Web Services inked a technological integration agreement to utilize artificial intelligence models to collect and analyze imaging data for enhancing existing diagnostic workflow.
Moreover, a significant number of product development agreements have also been signed in the virtual biopsy market, examples include collaboration between GE Healthcare and Elekta.
In the past two years, nearly 85 patents focused on virtual biopsy have been granted / filed, indicating the efforts made by researchers in this domain. It is worth highlighting that majority of the patents in this domain were patent applications (60%, not having received approval yet), followed by granted patents.
In recent years, several instances of funding and investments have been established, enabling virtual biopsy developers to expand their product portfolio and accelerate company growth in this domain. It is worth highlighting that funding and investments made in this industry have been primarily focused on grant / awards, supporting new companies to enter into the market. For instance, in 2023, Darmiyan received grant / awards worth USD 0.4 million the Centre from Aging + Brain Health Innovation to early detect, visualize, and quantify neurodegenerative disorders.
The global market for virtual biopsy is estimated to be worth USD 0.85 billion in 2026. Driven by the increase in the demand for rapid and efficient diagnostic tools, the virtual biopsy devices market is anticipated to grow at a CAGR of 15% during the forecast period, till 2035. This can be attributed to the increase in the cases of cancer mortality which require faster and more efficient diagnostic tools such as virtual biopsy for efficient patient care management.
Currently, ~40% of the virtual biopsy market share is captured by North America, driven by an increasing demand for safer and more effective healthcare devices for early screening and diagnosis of ailments in this region. This requirement of early diagnostic tools increased the need of precise healthcare devices such as virtual biopsy for rapid and precise sample analysis of the patients. It is worth highlighting that the market size in Latin America is expected to grow at a higher CAGR (11.55%), during the forecast period.
Over the years, there has been a growing demand for efficient and safe screening diagnostic tools to enhance patient care management. The National Cancer Institute (NCI) projects that global cancer mortality will rise to 15.3 million by 2040, highlighting an urgent need for effective early detection tools. By utilizing advanced screening devices such as virtual biopsy, cancer can be detected before further propagation, which can help reduce mortality rates. As virtual biopsy techniques play a crucial role in the screening of various diseases, developers are actively engaged in the development of innovative virtual biopsy devices to address the unmet needs of healthcare.
The conventional way of diagnosing cancer and other physiological disorders requires surgical sample extraction which is time consuming and painful. Additionally, sometimes the sample under consideration is deep-seated which cannot be easily acquired without damaging surrounding healthy tissue, thereby leading to serious complications while surgical extraction of samples including infections and excessive bleeding.
To overcome these aforementioned challenges, advanced diagnostic tools, such as virtual biopsies can provide results almost immediately after non invasive image acquisition procedure. Thus, incorporating virtual biopsy devices aids in expediting treatment decisions, providing safer means of diagnosis and enhancing patient outcome.
To enhance patient convenience, several companies are shifting from actual sample collection to image acquisition, providing a safer data extraction approach through imaging technologies. For instance, in 2024, Quibim commercialized a device named QP-Liver®, which utilizes magnetic resonance imaging (MRI) technology to capture image of the sample for further analysis of liver abnormalities. Additionally, other imaging technologies such as computed tomography (CT) and optical coherence tomography (OCT) are also available for extracting high resolution images.
Examples of top players in virtual biopsy industry (have been profiled in this market report; in alphabetical order) include City Imaging and Clinical Labs, GE Healthcare, Imaging Biometrics, ImageBiopsy Lab, Median Technologies, OptoVibronex, Quibim and Siemens Healthineers. This market report includes an easily searchable excel database of all the virtual biopsy developers present worldwide.
The market report presents an in-depth virtual biopsy devices market analysis, highlighting the capabilities of various virtual biopsy device developers in this market, across different segments. Amongst other elements, the market report includes:
Driven by numerous developmental breakthroughs and results of studies demonstrating the vast potential of virtual biopsy in enhancing advanced patient care management have garnered considerable attention of various market players engaged in the healthcare industry. Several developments have taken place in the field of virtual biopsy over the past few years. Some of these recent initiatives have been mentioned below. These developments, even if they took place post the release of our market report, substantiate the overall virtual biopsy market trends that have been outlined in our analyses.